Trade Merus NV - MRUS CFD

Merus NV (NASDAQ: MRUS) is a clinical-stage oncology company developing bispecific antibody therapeutics for solid tumours and blood cancers. Its Biclonics® platform creates antibodies that bind to two targets simultaneously, aiming to improve tumour specificity and immune activation. With multiple candidates in mid- to late-stage trials and partnerships with leading biopharma firms, Merus is a high-potential player in next-generation cancer immunotherapy.